Gene therapy for pediatric AIDS

Gerhard Bauer, D. Selander, B. Engel, D. Carbonaro, S. Csik, S. Rawlings, J. Church, D. B. Kohn

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Gene therapy is an experimental treatment modality under investiation for applications to HIV-1 infection. We have developed retroviral vectors carrying anti-HIV-1 genes, demonstrated that these genes cause significant suppression of HIV-1 replication in cultures of primary hematopoietic cells, and performed a clinical trial in pediatric AIDS patients. Four HIV-1-infected children and adolescents underwent bone marrow harvest from which CD34+ cells were isolated and transduced by a retroviral vector carrying an RRE decoy gene. The cells were re-infused into the subjects, without complications, showing that gene transfer in pediatric AIDS patients is safe and feasible. However, gene-containing leukocytes in the peripheral blood were seen only at a low level and only in the first months following cell infusion. To attain some degree of efficacy, it will be necessary to achieve a higher level of gene transfer and to obtain sustained gene expression. We are currently developing new gene transfer methods and vectors designed to improve the results in future trials. If it becomes possible to reach the ideal goal of producing high percentages of T lymphocytes and monocytic cells that are resistant to HIV-1 infection, gene therapy could serve as a complement to antiretroviral drug therapy and help to sustain immunologic function.

Original languageEnglish (US)
Pages (from-to)318-329
Number of pages12
JournalAnnals of the New York Academy of Sciences
Volume918
StatePublished - 2000
Externally publishedYes

Fingerprint

Gene therapy
Pediatrics
Gene transfer
Genetic Therapy
Acquired Immunodeficiency Syndrome
Genes
HIV-1
Drug therapy
T-cells
HIV Infections
Gene expression
Bone
Blood
Primary Cell Culture
Gene Therapy
AIDS/HIV
Gene
Leukocytes
Bone Marrow
Cells

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Bauer, G., Selander, D., Engel, B., Carbonaro, D., Csik, S., Rawlings, S., ... Kohn, D. B. (2000). Gene therapy for pediatric AIDS. Annals of the New York Academy of Sciences, 918, 318-329.

Gene therapy for pediatric AIDS. / Bauer, Gerhard; Selander, D.; Engel, B.; Carbonaro, D.; Csik, S.; Rawlings, S.; Church, J.; Kohn, D. B.

In: Annals of the New York Academy of Sciences, Vol. 918, 2000, p. 318-329.

Research output: Contribution to journalArticle

Bauer, G, Selander, D, Engel, B, Carbonaro, D, Csik, S, Rawlings, S, Church, J & Kohn, DB 2000, 'Gene therapy for pediatric AIDS', Annals of the New York Academy of Sciences, vol. 918, pp. 318-329.
Bauer G, Selander D, Engel B, Carbonaro D, Csik S, Rawlings S et al. Gene therapy for pediatric AIDS. Annals of the New York Academy of Sciences. 2000;918:318-329.
Bauer, Gerhard ; Selander, D. ; Engel, B. ; Carbonaro, D. ; Csik, S. ; Rawlings, S. ; Church, J. ; Kohn, D. B. / Gene therapy for pediatric AIDS. In: Annals of the New York Academy of Sciences. 2000 ; Vol. 918. pp. 318-329.
@article{8539be3938824582a9b5844e9c91fdde,
title = "Gene therapy for pediatric AIDS",
abstract = "Gene therapy is an experimental treatment modality under investiation for applications to HIV-1 infection. We have developed retroviral vectors carrying anti-HIV-1 genes, demonstrated that these genes cause significant suppression of HIV-1 replication in cultures of primary hematopoietic cells, and performed a clinical trial in pediatric AIDS patients. Four HIV-1-infected children and adolescents underwent bone marrow harvest from which CD34+ cells were isolated and transduced by a retroviral vector carrying an RRE decoy gene. The cells were re-infused into the subjects, without complications, showing that gene transfer in pediatric AIDS patients is safe and feasible. However, gene-containing leukocytes in the peripheral blood were seen only at a low level and only in the first months following cell infusion. To attain some degree of efficacy, it will be necessary to achieve a higher level of gene transfer and to obtain sustained gene expression. We are currently developing new gene transfer methods and vectors designed to improve the results in future trials. If it becomes possible to reach the ideal goal of producing high percentages of T lymphocytes and monocytic cells that are resistant to HIV-1 infection, gene therapy could serve as a complement to antiretroviral drug therapy and help to sustain immunologic function.",
author = "Gerhard Bauer and D. Selander and B. Engel and D. Carbonaro and S. Csik and S. Rawlings and J. Church and Kohn, {D. B.}",
year = "2000",
language = "English (US)",
volume = "918",
pages = "318--329",
journal = "Annals of the New York Academy of Sciences",
issn = "0077-8923",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Gene therapy for pediatric AIDS

AU - Bauer, Gerhard

AU - Selander, D.

AU - Engel, B.

AU - Carbonaro, D.

AU - Csik, S.

AU - Rawlings, S.

AU - Church, J.

AU - Kohn, D. B.

PY - 2000

Y1 - 2000

N2 - Gene therapy is an experimental treatment modality under investiation for applications to HIV-1 infection. We have developed retroviral vectors carrying anti-HIV-1 genes, demonstrated that these genes cause significant suppression of HIV-1 replication in cultures of primary hematopoietic cells, and performed a clinical trial in pediatric AIDS patients. Four HIV-1-infected children and adolescents underwent bone marrow harvest from which CD34+ cells were isolated and transduced by a retroviral vector carrying an RRE decoy gene. The cells were re-infused into the subjects, without complications, showing that gene transfer in pediatric AIDS patients is safe and feasible. However, gene-containing leukocytes in the peripheral blood were seen only at a low level and only in the first months following cell infusion. To attain some degree of efficacy, it will be necessary to achieve a higher level of gene transfer and to obtain sustained gene expression. We are currently developing new gene transfer methods and vectors designed to improve the results in future trials. If it becomes possible to reach the ideal goal of producing high percentages of T lymphocytes and monocytic cells that are resistant to HIV-1 infection, gene therapy could serve as a complement to antiretroviral drug therapy and help to sustain immunologic function.

AB - Gene therapy is an experimental treatment modality under investiation for applications to HIV-1 infection. We have developed retroviral vectors carrying anti-HIV-1 genes, demonstrated that these genes cause significant suppression of HIV-1 replication in cultures of primary hematopoietic cells, and performed a clinical trial in pediatric AIDS patients. Four HIV-1-infected children and adolescents underwent bone marrow harvest from which CD34+ cells were isolated and transduced by a retroviral vector carrying an RRE decoy gene. The cells were re-infused into the subjects, without complications, showing that gene transfer in pediatric AIDS patients is safe and feasible. However, gene-containing leukocytes in the peripheral blood were seen only at a low level and only in the first months following cell infusion. To attain some degree of efficacy, it will be necessary to achieve a higher level of gene transfer and to obtain sustained gene expression. We are currently developing new gene transfer methods and vectors designed to improve the results in future trials. If it becomes possible to reach the ideal goal of producing high percentages of T lymphocytes and monocytic cells that are resistant to HIV-1 infection, gene therapy could serve as a complement to antiretroviral drug therapy and help to sustain immunologic function.

UR - http://www.scopus.com/inward/record.url?scp=0033635758&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033635758&partnerID=8YFLogxK

M3 - Article

C2 - 11131719

AN - SCOPUS:0033635758

VL - 918

SP - 318

EP - 329

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

SN - 0077-8923

ER -